Bee Choo Tai

National University of Singapore — Singapore

Medicine · Health Sciences

40h-index6.7kcitations297works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(33), Obesity, Physical Activity, Diet(15), Head and Neck Cancer Studies(13), Mobile Health and mHealth Applications(12), Advanced Breast Cancer Therapies(12)

Publications295 total

Longitudinal Association Between Disc Hemorrhage and Primary Open-Angle Glaucoma Progression: A Systematic Review and Meta-Analysis
Ophthalmic Epidemiology·2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial
The Lancet Oncology·2026· 1 cited
Longitudinal Association Between Disc Hemorrhage and Primary Open-Angle Glaucoma Progression: A Systematic Review and Meta-Analysis
Figshare·2026Open Access
Longitudinal Association Between Disc Hemorrhage and Primary Open-Angle Glaucoma Progression: A Systematic Review and Meta-Analysis
Figshare·2026Open Access
Estimating treatment effect in randomised controlled trials with continuous outcomes subject to non-compliance: a logistic regression-based multiple imputation approach
Trials·2025Open Access
Augmenting Large Language Models With National Comprehensive Cancer Network Guidelines for Improved and Standardized Adjuvant Therapy Recommendations in Postoperative Breast Cancer Cases
JCO Clinical Cancer Informatics·2025Open Access
Protocol for a randomized controlled trial of steroid versus methotrexate as first-line monotherapy in the management of idiopathic granulomatous mastitis
PLoS ONE·2025Open Access
Movement and dietary behaviours and mental health among university students: the Health@NUS study
BMC Public Health·2025Open Access
Supplementary Data S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S3 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S3 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S5 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S6 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
page 1 of 15Next →

Frequent Co-authors

E Shyong Tai(7), Gerald Choon‐Huat Koh(6), Ross A. Soo(4), Wen Cai Zhang(3), Ng Shyh‐Chang(3), Min En Nga(3), Yin Huei Pang(3), Elaine Hsuen Lim(3), Bing Lim(3), Eng Huat Tan(3), Zhaojin Chen(3), Kee Seng Chia(3), Derrick Heng(3), Peng Choong Lau(3), Amit Rai(2), Shivshankar Umashankar(2), Boon-Seng Soh(2), Kishore Bhakoo(2), Senthil Raja Jayapal(2), Massimo Nichane(2)